NRG Oncology #GU Cancer Committee trial portfolio. Great lineup, glad to say @CSCancerCare participating in #GU007 NADIR (NCT04037254) and #RTOG STEEL (NCT03809000) led by study chair Edwin Posadas, MD great Winter 2022 session #nrg2022 ! Felix Feng Todd 〽️ Morgan, MD Sean Sachdev, MD #pcsm

Attend this upcoming #SNMMI Dinner Symposium, April 4 in Chicago with @vanderweelemd Phillip Koo, MD Sean Sachdev, MD Ashley Ross MD PhD to explore new/recently approved radiopharmaceuticals being used to identify & treat local & metastatic #ProstateCancer snmmi.org/PSMAChicago

This is the science we are here for. Groundbreaking #ASTRO22 presentation by Erin Gillespie, MD MPH in RANDOMIZED trial for asymptomatic #bonemets with reduced #SRE and improved overall survival.ASTRO #wow

Ryan Hughes at presidential: a nice framework for thinking about toxicity/QoL assessment ⬇️. Did you know in an EORTC review of >200 trials, >60% had significant differences in PROs, ~75% of which were in global domains? ➡️ bit.ly/3gAldBr - #ASTRO2022 #radonc OncoAlert

As we’ve seen before, Jonathan Tward demonstrating the impressive performance of AI analysis of pathology slide data from older RTOG trials in being able to predict clinical outcomes. #pcsm #ASTRO22

From lab of Craig Horbinski, resident Mark Youngblood showing how docetaxel may serve as a potent radiosensitizer in molecularly selected high risk meningiomas. Neurosurgery at NM Malnati Brain Tumor Institute at Northwestern #SNO2022

The Atique Ahmed, PhD lab showing that ARF4 upregulation may serve to increase treatment resistance; a potential target for improved outcomes in GBM. #SNO2022 #btsm

Long term results of RTOG 9802 (median FU 16.1y) showing it may be reasonable to observe some pts with low risk (GTR, Age <40) LGG. Small tumor and minimal residual (per MRI) important variables in predicting better outcomes. Molecular analyses awaited. #SNO2022 #btsm

🔥🔥 primary endpoint analysis from Nicholas van As of PACE-A; SBRT versus robotic prostatectomy for #prostatecancer RCT. Co-primary toxicity endpoints (continence/bowel) #GU23 ASCO OncoAlert NHS. N=123, SBRT had ⬇️ pad use ⬇️ sexual dysfunction but ⬆️ bowel bother. All low grade.

Mature outcome data from the landmark, practice changing CHHIP trial presented by Prof Joe O'Sullivan The Patrick G Johnston Centre for Cancer Research. 60Gy very close to being superior to 74Gy. Superb data. Prof Emma Hall Follow us on Bluesky @ICR-CTSU #GU23

TRIP did not demonstrate the superiority of 30 months vs. 6 months of ADT when combined with brachytherapy and EBRT.! Atsunori Yorozu, MD, PhD #GU23 ASCO OncoAlert UroToday.com Prostate Cancer Foundation Oncology Brothers Advanced Prostate Cancer Consensus Conference Hem-Onc Fellows Network #prostatecancer Uromigos #MedTwitter

Had a blast giving a talk and hanging out with Northwestern Medicine #radonc residents and students as visiting professor! The future is bright for our field! 🌟☢️ Sean Sachdev, MD James Randall Salah Dajani Amulya Yalamanchili, MD George E. Naoum, MD @Zheng_Shuhua @WashURadOnc

👩‍🏫📚🎉 Congratulations to our Dr. Luther Brady Educational Grant winners! 🎉📚👩‍🏫 Amulaya Yalamanchili, Northwestern University, @amulyayala Michelle Tibbs UC San Diego Rad Med Shelley (Michelle) Tibbs Ramez Kouzy MD Anderson Cancer Center Ramez Kouzy, MD Michael Rooney MD Anderson Cancer Center Michael Rooney

ASTRO PLENARY Session LBA 04 Randomized trial PCI vs HA-PCI: HA-PCI is a standard of care for Small cell lung cancer

ASTRO Plenary: 5-fraction SBRT/SABR non-inferior at 5y compared to more protracted treatment (PACE-B). Detailed toxicity reporting, great work by Nicholas van As Alison Tree 💙 Follow us on Bluesky @ICR-CTSU #ASTRO23

Happy to see Melanie of Lurie Cancer Center represent at #ASCO24 in full #purpleglory

Really honored and humbled to receive the 2024 Christopher Getch Clinical Excellence Award from Neurosurgery at NM Proud to participate in the care of brain tumor patients and contribute to the education of neurosurgery residents #btsm

Honored to host Dr. Albert Koong Albert Koong, MD PhD, Chair of RadOnc at MD Andreson, as the distinguished speaker for our annual resident retreat. He started us off with a wonderful talk this morning.

On Monday, I will present the key PARTIQoL trial results at the 2024 ASTRO Annual Meeting! 🎉 I'll cover the potential benefits of #ProtonTherapy, & innovative patient recruitment strategies. Let me know if you are attending #ASTRO2024 too!

🏹 Randomized Phase III Trial: Adaptive Radiation and Chemotherapy For Muscle Invasive Bladder Cancer (ARCHER) Congratulations to the NRG GU015 ARCHER study team led by Scott E Delacroix Jr M.D. and Himanshu Nagar for the recent activation and launch of this cutting-edge and patient-centric